MedTrace Logo

Determine the Effect of Multiple Doses of AZD7325, CYP Study

NCT00790114 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2008-11-13

No results posted yet for this study

Summary

To determine the effects of repeated doses of AZD7325 on the pharmacokinetic profile of a CYP3A4 substrate (midazolam and its 1' hydroxy metabolite) and a CYP1A2 substrate (caffeine and its paraxanthine \[3-desmethyl\] metabolite).

Conditions

  • Healthy Volunteer

Interventions

DRUG

AZD7325

Oral, day 1-12

DRUG

Midazolam

single dose, twice during treatment

DRUG

Caffeine

single dose, twice during treatment

Sponsors & Collaborators

Principal Investigators

  • Darren Wilbraham, MBBS, DCPSA · Guy's Drug Research Unit Quintiles

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2008-09-30
Completion
2008-09-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00790114 on ClinicalTrials.gov